Broncus Holding Corporation logo

Broncus Holding Corporation

2216.HK

HKSEHealthcareMedical - Devices

Latest quote

HK$0.645

+HK$0.01 · +1.57%

Aug 21, 4:08 PM HKT

2216.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international territories. The company's innovative product lineup includes advanced navigation systems such as LungPoint Virtual Bronchoscopic Navigation, a sophisticated computer-assisted image-based software solution. It also offers LungPoint Plus, a system providing real-time airway guidance crucial for lung biopsies and other medical interventions, and LungPro, a virtual bronchoscopic navigation product that enables three-dimensional real-time guided transbronchial needle aspiration alongside proprietary parenchymal navigation. Beyond navigation, Broncus provides a suite of therapeutic products. These feature InterVapor, a targeted bronchoscopic thermal vapor ablation system designed to treat diseased, hyper-inflated lung segments. Additionally, it offers an RF Generator paired with an RF Ablation Catheter, forming a radiofrequency ablation system specifically developed to target lung cancer. The H-Marker, a pulmonary surgical marker, is another key offering. The company further supplies a range of specialized procedural devices, including the BioStarNeedle, a single-use ultrasound-guided aspiration needle for retrieving tissue samples, and the FleXNeedle, a versatile multipurpose biopsy needle. Complementing these are various bronchoscopic accessories like the Archimedes Sheath, a sterile, single-use flexible tube that serves as a working channel during bronchoscopic procedures. The Archimedes Dilation Balloon, another sterile, single-use flexible tube with a distal balloon, is used to dilate target lung tissue within the bronchial tree after insertion through a bronchoscope or sheath. Finally, the Steerable Sheath provides a steerable adjustment handle and an additional working channel. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CN
CEO
Hong Xu
Listed since
Sep 24, 2021
Employees
191

Market position

52-week range

Current HK$0.645

Open
HK$0.645
Previous close
HK$0.635
Volume
202.5K
0.41× average
Average volume
498.53K
Average daily volume
Market cap
339.64M HKD
Beta
1.19
Market reference 1
50-day average
HK$0.6678
-3.41% below average
200-day average
HK$1.462
-55.88% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-2.22×
P/B (TTM)
0.27×
P/S (TTM)
248.67×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-1585.06%
Operating margin
-14017.85%
Net margin
-10273.01%

Financial health

Debt / equity
Altman Z-score
-0.24
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1490%-4149%-9788%-15428%Gross margin, FY2021: 80.27%Gross margin, FY2022: 77.71%Gross margin, FY2023: 70.47%Gross margin, FY2024: 75.50%Gross margin, FY2025: -527.01%Operating margin, FY2021: -365.93%Operating margin, FY2022: -347.48%Operating margin, FY2023: -323.95%Operating margin, FY2024: -276.57%Operating margin, FY2025: -14017.82%Net margin, FY2021: -2168.56%Net margin, FY2022: -297.84%Net margin, FY2023: -273.92%Net margin, FY2024: -188.21%Net margin, FY2025: -10272.99%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 80.27%. Gross margin FY2022 77.71%. Gross margin FY2023 70.47%. Gross margin FY2024 75.50%. Gross margin FY2025 -527.01%. Operating margin FY2021 -365.93%. Operating margin FY2022 -347.48%. Operating margin FY2023 -323.95%. Operating margin FY2024 -276.57%. Operating margin FY2025 -14017.82%. Net margin FY2021 -2168.56%. Net margin FY2022 -297.84%. Net margin FY2023 -273.92%. Net margin FY2024 -188.21%. Net margin FY2025 -10272.99%.

Income trends

Revenue

174K USD-97.86%

Operating income

−24.39M USD-8.46%

Net income

−17.88M USD-16.81%
Income trends across reported periods35.6M USD−63.23M USD−162.06M USD−260.88M USDRevenue, FY2021: 10.89M USDRevenue, FY2022: 9.41M USDRevenue, FY2023: 10.26M USDRevenue, FY2024: 8.13M USDRevenue, FY2025: 174K USDOperating income, FY2021: −39.85M USDOperating income, FY2022: −32.71M USDOperating income, FY2023: −33.22M USDOperating income, FY2024: −22.49M USDOperating income, FY2025: −24.39M USDNet income, FY2021: −236.18M USDNet income, FY2022: −28.04M USDNet income, FY2023: −28.09M USDNet income, FY2024: −15.3M USDNet income, FY2025: −17.88M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 10.89M USD. Revenue FY2022 9.41M USD. Revenue FY2023 10.26M USD. Revenue FY2024 8.13M USD. Revenue FY2025 174K USD. Operating income FY2021 −39.85M USD. Operating income FY2022 −32.71M USD. Operating income FY2023 −33.22M USD. Operating income FY2024 −22.49M USD. Operating income FY2025 −24.39M USD. Net income FY2021 −236.18M USD. Net income FY2022 −28.04M USD. Net income FY2023 −28.09M USD. Net income FY2024 −15.3M USD. Net income FY2025 −17.88M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue174K USD8.13M USD10.26M USD9.41M USD10.89M USD
Cost of goods sold1.09M USD1.99M USD3.03M USD2.1M USD2.15M USD
Gross profit−917K USD6.14M USD7.23M USD7.32M USD8.74M USD
Research and development7.77M USD11.47M USD20.15M USD19.17M USD16.76M USD
Selling, general, and administrative15.7M USD15.76M USD20.42M USD20.42M USD31.25M USD
Operating expenses23.47M USD28.63M USD40.45M USD40.02M USD46.17M USD
Interest income5.49M USD6.53M USD6.04M USD2.63M USD161K USD
Interest expense4.01K USD84K USD163K USD98K USD170K USD
Depreciation and amortization1.71M USD2.12M USD2.87M USD2.13M USD2.69M USD
Operating income−24.39M USD−22.49M USD−33.22M USD−32.71M USD−39.85M USD
Net income−17.88M USD−15.3M USD−28.09M USD−28.04M USD−236.18M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
20%
1 beat, 2 misses, 2 met estimates
Average EPS surprise
-83.11%
5 comparable reports
Latest EPS result
-0.16

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.1-0.24-0.37-0.51Q3 '22MetQ1 '23BeatQ3 '23MetQ1 '24MissQ3 '24No estimateQ1 '25No estimateQ3 '25No estimateQ1 '26No estimate
Q3 2022, reported Aug 30, 2022: actual -0.235, estimate -0.235, surprise 0.00%, Met estimate. Q1 2023, reported Mar 29, 2023: actual -0.234, estimate -0.469, surprise +50.00%, Beat. Q3 2023, reported Aug 29, 2023: actual -0.235, estimate -0.235, surprise 0.00%, Met estimate. Q1 2024, reported Mar 28, 2024: actual -0.214, estimate -0.156, surprise -36.98%, Miss. Q3 2024, reported Aug 29, 2024: actual -0.156, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual -0.117, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 28, 2025: actual -0.157, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 31, 2026: actual -0.162, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates110.78M67M23.22M-20.56MQ3 '22MissQ1 '23MissQ3 '23BeatQ1 '24MissQ3 '24MissQ1 '25No estimateQ3 '25No estimateQ1 '26No estimate
Q3 2022, reported Aug 30, 2022: actual 25.26M HKD, estimate 29.53M HKD, surprise -14.46%, Miss. Q1 2023, reported Mar 29, 2023: actual 48.39M HKD, estimate 81.99M HKD, surprise -40.98%, Miss. Q3 2023, reported Aug 29, 2023: actual 41.03M HKD, estimate 40.75M HKD, surprise +0.67%, Beat. Q1 2024, reported Mar 28, 2024: actual 39.21M HKD, estimate 101.69M HKD, surprise -61.44%, Miss. Q3 2024, reported Aug 29, 2024: actual 28.93M HKD, estimate 101.72M HKD, surprise -71.56%, Miss. Q1 2025, reported Mar 31, 2025: actual 34.39M HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 28, 2025: actual 12.97M HKD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 31, 2026: actual -11.5M HKD, estimate —, surprise —, Comparison unavailable.

2216.HK peers

Continue in GoAI

Research 2216.HK

research.disclaimer